A randomised trial of a pre-synaptic stimulator of DA2-dopaminergic and α2-adrenergic receptors on morbidity and mortality in patients with heart failure

European Journal of Heart Failure

Volumn 10, Issue 1, 2008, Pages 89-95

  Torp Pedersen, Christian ^a   Køber, Lars ^b   Carlsen, Jan E ^c   Akkan, Dilek ^d   Bruun, Niels E ^d   Dacoronias, Dimitri ^e   Dickstein, Kenneth ^f   Haghfelt, Torben ^g   Öhlin, Hans ^h   McMurray, John JV ⁱ  

^a BISPEBJERG HOSPITAL   (Denmark)

^b Rigshospitalet   (Denmark)

^c Cyncron   (Denmark)

^d GENTOFTE UNIVERSITY HOSPITAL   (Denmark)

^e CHIESI FARMACEUTICI S P A   (Italy)

^f UNIVERSITY OF BERGEN   (Norway)

^g ODENSE UNIVERSITY HOSPITAL   (Denmark)

^h LUND UNIVERSITY HOSPITAL   (Sweden)

ⁱ WESTERN INFIRMARY   (United Kingdom)

Author keywords

Controlled clinical trial; Heart failure; Nolomirole; Survival

Indexed keywords

ANGIOTENSIN RECEPTOR ANTAGONIST; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; NOLOMIROLE; PLACEBO; SPIRONOLACTONE;

AGED; ARTICLE; BLOOD PRESSURE; CAUSE OF DEATH; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CREATININE BLOOD LEVEL; DIZZINESS; DOUBLE BLIND PROCEDURE; DYSPNEA; FEMALE; FOLLOW UP; HEART FAILURE; HEART LEFT VENTRICLE FAILURE; HEART RATE; HOSPITALIZATION; HUMAN; MAJOR CLINICAL STUDY; MALE; MORBIDITY; MORTALITY; MULTICENTER STUDY; PNEUMONIA; POTASSIUM BLOOD LEVEL; PRIORITY JOURNAL; QUALITY OF LIFE; RANDOMIZED CONTROLLED TRIAL; SIDE EFFECT; TREATMENT OUTCOME; WALKING;

AGED; DOUBLE-BLIND METHOD; ESTERS; FEMALE; HEART FAILURE; HOSPITALIZATION; HUMANS; KAPLAN-MEIERS ESTIMATE; MALE; PROSPECTIVE STUDIES; RECEPTORS, ADRENERGIC, ALPHA-2; RECEPTORS, DOPAMINE D2; TETRAHYDRONAPHTHALENES; TIME FACTORS; TREATMENT OUTCOME; VENTRICULAR DYSFUNCTION, LEFT;

EID: 37549062578     PISSN: 13889842     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ejheart.2007.10.012     Document Type: Article

References (13)

1. Poole-Wilson P.A., Swedberg K., Cleland J.G., et al. Comparison of carvedilol and metoprolol on clinical outcomes in patients with chronic heart failure in the Carvedilol Or Metoprolol European Trial (COMET): randomised controlled trial. Lancet 362 9377 (2003) 7-13
2. Cohn J.N., Pfeffer M.A., Rouleau J., Sharpe N., et al. Adverse mortality effect of central sympathetic inhibition with sustained-release moxonidine in patients with heart failure (MOXCON). Eur J Heart Fail 5 5 (2003) 659-667
3. Razzetti R., Pastore F., Riunno M., et al. Haemodynamic and neurohormones release inhibiting effects of a DA2/alpha2 agonist. Eur J. Heart Fail suppl2 (2000) 94
4. Latini R., Jeremic G., Luvarà G., et al. Reduction of sympathetic drive and collagen deposition with a DA2 agonist in an experimental model of left ventricular dysfunction after myocardial infarction. Eur J Heart Fail suppl August (1997) 513
5. Morisco C., Ricciardelli B., Argenziano L., et al. Hemodynamic effects of graded oral doses of a new dopaminergic analogue CHF 1035 in patients with congestive heart failure. JACC (1995) p128A February
6. Tjeerdsma G., vanWijk L., Molhoek G., Boosma F., Hasskma J., and van Veldhuisen D. Autonomic and haemodynamic effects of a novel, selective, dopaminergic receptor agonist (CHF 1035) in chronic heart failure. Eur Heart J 21 (2000) Abstract 1851
7. Tjeerdsma G., van Wijk L.M., Molhoek G.P., Boomsma F., Haaksma J., and van Veldhuisen D.J. Autonomic and hemodynamic effects of a new selective dopamine agonist, CHF1035, in patients with chronic heart failure. Cardiovasc Drugs Ther 15 2 (2001) 139-145
8. Køber L., Torp-Pedersen C., Carlsen J., Videbaek R., and Egeblad H. An echocardiographic method for selecting high risk patients shortly after acute myocardial infarction, for inclusion in multi-centre studies (as used in the TRACE study). on behalf of the TRACE study group. Eur Heart J 15 (1994) 1616-1620
9. Berning J., Rokkedal Nielsen J., Launbjerg J., Fogh J., Mickley H., and Andersen P.E. Rapid estimation of left ventricular ejection fraction in acute myocardial infarction by echocardiographic wall motion analysis. Cardiology 80 3-4 (1992) 257-266
10. Køber L., Torp-Pedersen C., Carlsen J.E., et al. A Clinical Trial of the Angiotensin Converting Enzyme Inhibitor Trandolapril in patients with left ventricular dysfunction after myocardial infarction. The TRACE study group. N. Engl J Med 333 (1995) 1670-1676
11. Torp-Pedersen C., Moller M., Bloch-Thomsen P.E., et al. Dofetilide in patients with congestive heart failure and left ventricular dysfunction. Danish investigations of arrhythmia and mortality on dofetilide study group. N Engl J Med 341 12 (1999) 857-865
12. Kober L., Bloch-Thomsen P.E., Moller M., et al. Effect of dofetilide in patients with recent myocardial infarction and left-ventricular dysfunction: a randomised trial. Lancet 356 9247 (2000) 2052-2058
13. Torp-Pedersen C., Kober L., Ball S., et al. The incomplete Bucindolol Evaluation in Acute myocardial infarction Trial (BEAT). Eur J Heart Fail 4 4 (2002) 495